AdvanCell, an Australia-based radiopharmaceutical company, has raised $112m as investor interest in the radiopharma sector ...

Bristol Myers Squibb Co. closed 1.88% below its 52-week high of $61.10, which the company reached on January 27th.

These launches are positioned for multi-blockbuster status, thanks to their promise of fulfilling unmet needs, impacting ...

Researchers at the Johns Hopkins Kimmel Cancer Center have developed a computer model to help scientists identify tumor-fighting immune cells in patients with lung cancer treated with immune ...

The CHMP recommends approval of Bristol Myers' Opdivo plus Yervoy for the first-line treatment of hepatocellular carcinoma ...

New heart health biopharmaceutical company Kardigan, which counts among its co-founders the director for Northwestern ...

Biotech giant Bristol-Myers Squibb Company BMY is scheduled to report its fourth-quarter and full-year 2024 results on Feb. 6 ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

We recently published an article titled Jim Cramer’s Game Plan: 15 Stocks in Focus. In this article, we are going to take a ...

Researchers at the Johns Hopkins Kimmel Cancer Center and Bloomberg~Kimmel Institute for Cancer Immunotherapy have developed a computer model to help scientists identify tumor-fighting immune cells in ...

Such companies can be wonderful options for income-seeking investments. If you're in the market for that combo, let's ...

AdvanCell has secured $112 million in a Sanofi Ventures-backed series C funding round as the Australian radiopharma company ...